Aug 4 2010
Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.
Citigroup Global Markets Inc. is acting as sole book-running manager, Piper Jaffray & Co. is acting as co-lead manager and Canaccord Genuity Inc. and JMP Securities are acting as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., Prospectus Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 or by calling 877-858-5407. The Securities and Exchange Commission declared a registration statement relating to these securities effective on August 2, 2010.
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke